June 2026 Quarterly activity report & Appendix 4C
Filed with ASX · · 9 pages · English
Actinogen Medical Limited on 6ix
Story so far
Earlier from Actinogen Medical
- Xanamem depression trial published in British J Psychiatry
- ACW third positive XanaMIA trial data committee review
- Actinogen receives positive EMA scientific advice aligned with prior FDA guidance for its Alzheimer’s disease program
- Actinogen receives positive scientific advice from EMA
- Correction-March2026 quarterly activity report & Appendix 4C
Later from Actinogen Medical
- ACW Appendix 4E and 2026 annual report
- ACW FY2026 results and outlook
- ACW unlisted options fully underwritten
- ACW Alzheimers pivotal trial completes last patient visit
- Underwriting of unlisted options completed
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical